Matches in Wikidata for { <http://www.wikidata.org/entity/Q37474061> ?p ?o ?g. }
- Q37474061 description "article científic" @default.
- Q37474061 description "article scientifique" @default.
- Q37474061 description "articolo scientifico" @default.
- Q37474061 description "artigo científico" @default.
- Q37474061 description "artículu científicu espublizáu en 2009" @default.
- Q37474061 description "bilimsel makale" @default.
- Q37474061 description "scientific article published on 26 October 2009" @default.
- Q37474061 description "vedecký článok" @default.
- Q37474061 description "vetenskaplig artikel" @default.
- Q37474061 description "videnskabelig artikel" @default.
- Q37474061 description "vědecký článek" @default.
- Q37474061 description "wetenschappelijk artikel" @default.
- Q37474061 description "wissenschaftlicher Artikel" @default.
- Q37474061 description "наукова стаття, опублікована в жовтні 2009" @default.
- Q37474061 description "научни чланак" @default.
- Q37474061 description "مقالة علمية نشرت في 26 أكتوبر 2009" @default.
- Q37474061 name "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 name "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 name "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 type Item @default.
- Q37474061 label "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 label "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 label "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 prefLabel "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 prefLabel "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 prefLabel "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 P1433 Q37474061-80A8F568-A059-4676-B3D5-F0866E7451D8 @default.
- Q37474061 P1476 Q37474061-EE8E80DA-5EEF-42B3-8166-47CEAA05EE7A @default.
- Q37474061 P2093 Q37474061-0B8CFB93-8DCE-4FED-82D5-0FDBC9A56B63 @default.
- Q37474061 P2093 Q37474061-10DAD02E-0AA2-44ED-A7D7-7E2B9871FE06 @default.
- Q37474061 P2093 Q37474061-56294DB4-DEF3-46C3-8EAD-E213A46FB8F7 @default.
- Q37474061 P2093 Q37474061-5998E58D-C29C-476B-A721-BAC87ECF1F8A @default.
- Q37474061 P2093 Q37474061-6CEBDCDB-E3B4-4F97-BF40-AA1A502B79D8 @default.
- Q37474061 P2093 Q37474061-879FF740-2227-440E-81F9-F500E6B0C457 @default.
- Q37474061 P2093 Q37474061-8BCC5642-45EF-4E95-9F94-220FC4B0FF2F @default.
- Q37474061 P2093 Q37474061-93220979-715B-458F-B1E0-3290F3997101 @default.
- Q37474061 P2093 Q37474061-CBD7440F-D77C-41C7-B3BA-AFC419F9E117 @default.
- Q37474061 P2093 Q37474061-FAD94F50-9001-4593-B365-952728971107 @default.
- Q37474061 P2860 Q37474061-225DAD85-8A09-4C6E-8C64-0E4F412EA74E @default.
- Q37474061 P2860 Q37474061-253FF821-3896-44C6-B897-7EC53B08C464 @default.
- Q37474061 P2860 Q37474061-325333F4-09DA-43D6-9EC3-EB05C3FDF41A @default.
- Q37474061 P2860 Q37474061-3C6E6902-D08A-4EF4-B840-FC90A426BECB @default.
- Q37474061 P2860 Q37474061-3EA7A48C-2DCB-4927-A550-4D27C967E34B @default.
- Q37474061 P2860 Q37474061-4A0EADE4-1CCF-4282-B8A8-277CA47F5B70 @default.
- Q37474061 P2860 Q37474061-52508B7B-AF0B-4F36-817C-8D84AC037703 @default.
- Q37474061 P2860 Q37474061-64D67AE9-027E-49ED-B76F-0B60B3EDE309 @default.
- Q37474061 P2860 Q37474061-81CF9364-8FB7-4D72-B750-345389076B38 @default.
- Q37474061 P2860 Q37474061-8A5EA732-9EB9-4AC4-A0E4-7EB72D1FF7D6 @default.
- Q37474061 P2860 Q37474061-8B2B039D-BC42-4A83-ACDC-BAE461B3893D @default.
- Q37474061 P2860 Q37474061-8D7829FD-FDAB-4DBD-8044-F7D093B4B0FF @default.
- Q37474061 P2860 Q37474061-92D5C6AD-F1CD-43AF-95E4-B10760F38C06 @default.
- Q37474061 P2860 Q37474061-A7289632-44CD-4824-9D62-AA37257E04A4 @default.
- Q37474061 P2860 Q37474061-A7503A17-350B-4BDF-BD4D-A8A06DB7E0B9 @default.
- Q37474061 P2860 Q37474061-B99A38AA-52E4-4DFD-B933-009FFAE6113E @default.
- Q37474061 P2860 Q37474061-B9F38D74-FF1A-4790-9221-70D90A265FDD @default.
- Q37474061 P2860 Q37474061-CB4DBBFA-0752-4BFF-8FBA-A83092F429E8 @default.
- Q37474061 P2860 Q37474061-CE997B7D-D0F0-447C-86F3-39767680114B @default.
- Q37474061 P2860 Q37474061-EB3D6D98-BFCE-4023-A4DD-E45E4EF79702 @default.
- Q37474061 P304 Q37474061-7353E222-B326-4B65-8729-8CAC87604810 @default.
- Q37474061 P31 Q37474061-59F0067C-8AE8-4774-BEB5-5A685E6D3C55 @default.
- Q37474061 P356 Q37474061-402936BD-B8ED-48B5-BEDF-EF793B72DB1D @default.
- Q37474061 P407 Q37474061-45144D5F-3494-4547-84A2-2CDDBBFA7540 @default.
- Q37474061 P433 Q37474061-058F0EE3-D0F2-48D1-9C49-58BB8CDFA148 @default.
- Q37474061 P478 Q37474061-4E38F376-FFE2-41CA-951E-68DF5D95AA12 @default.
- Q37474061 P577 Q37474061-24F21403-6E9E-434D-B561-5CE8E43FF0F7 @default.
- Q37474061 P5875 Q37474061-48F3BA5F-340F-41DD-B746-4AA421A64BA8 @default.
- Q37474061 P698 Q37474061-020FFBAF-CD75-42E8-9CAA-6A41AAA91D90 @default.
- Q37474061 P921 Q37474061-4ACA964D-4C93-4A82-AE4E-E9C3121DCDEE @default.
- Q37474061 P921 Q37474061-4E402513-73F8-47EB-A8EA-D0BA3222604D @default.
- Q37474061 P921 Q37474061-5161E019-D0DB-4E8A-B616-C3C0CCC93C7E @default.
- Q37474061 P921 Q37474061-A15AB3E9-AB78-4B5B-A40B-82C119DF5145 @default.
- Q37474061 P932 Q37474061-3273CB94-15AF-49AE-AD68-82A7F15E0881 @default.
- Q37474061 P356 JCO.2009.22.1309 @default.
- Q37474061 P698 19858396 @default.
- Q37474061 P1433 Q400292 @default.
- Q37474061 P1476 "Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904." @default.
- Q37474061 P2093 "Donna Niedzwiecki" @default.
- Q37474061 P2093 "Donna R Hollis" @default.
- Q37474061 P2093 "Hedy L Kindler" @default.
- Q37474061 P2093 "Margaret A Tempero" @default.
- Q37474061 P2093 "Matthew H Kulke" @default.
- Q37474061 P2093 "Michael Cusnir" @default.
- Q37474061 P2093 "Peter C Enzinger" @default.
- Q37474061 P2093 "Richard M Goldberg" @default.
- Q37474061 P2093 "Robert J Mayer" @default.
- Q37474061 P2093 "Stefan M Gorsch" @default.
- Q37474061 P2860 Q27860585 @default.
- Q37474061 P2860 Q29547565 @default.
- Q37474061 P2860 Q29619344 @default.
- Q37474061 P2860 Q33326148 @default.
- Q37474061 P2860 Q33335584 @default.
- Q37474061 P2860 Q33367733 @default.
- Q37474061 P2860 Q34550827 @default.
- Q37474061 P2860 Q34557866 @default.
- Q37474061 P2860 Q34570210 @default.
- Q37474061 P2860 Q34579882 @default.
- Q37474061 P2860 Q34581428 @default.
- Q37474061 P2860 Q36612255 @default.
- Q37474061 P2860 Q37124105 @default.
- Q37474061 P2860 Q40579509 @default.